High serum transforming growth factor-β1 levels predict outcome in hepatocellular carcinoma patients treated with sorafenib

Clinical Cancer Research

Volumn 21, Issue 16, 2015, Pages 3678-3684

  Lin, Tzu Hsuan ^a   Shao, Yu Yun ^a,b   Chan, Soa Yu ^b   Huang, Chung Yi ^b   Hsu, Chih Hung ^a,b   Cheng, Ann Lii ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIGEN; SORAFENIB; TRANSFORMING GROWTH FACTOR BETA1; UFT; CARBANILAMIDE DERIVATIVE; MESSENGER RNA; NICOTINAMIDE; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL VIABILITY; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SURVIVAL TIME; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; BLOOD; CARCINOMA, HEPATOCELLULAR; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; HEPG2 CELL LINE; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME;

EID: 84942330446     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1954     Document Type: Article

References (33)

1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
2. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepato-cellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
3. Shao YY, Hsu CH, Cheng AL. Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we? Liver Cancer 2013;2:93-107.
4. Massague J, Blain SW, Lo RS. TGF-β signaling in growth control, cancer, and heritable disorders. Cell 2000;103:295-309.
5. Wu MY, Hill CS. Tgf-b superfamily signaling in embryonic development and homeostasis. Dev Cell 2009;16:329-43.
6. Laouar Y, Sutterwala FS, Gorelik L, Flavell RA. Transforming growth factor-b controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma. Nat Immunol 2005;6:600-7.
7. Lawrence DA. Trans for ming growth factor-β:ageneral review. Eur Cytokine Netw 1996;7:363-74.
8. Principe DR, Doll JA, Bauer J, Jung B, Munshi HG, Bartholin L, et al. TGF-β: duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst 2014;106:djt369.
9. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-29.
10. Yamazaki K, Masugi Y, Sakamoto M. Molecular pathogenesis of hepato-cellular carcinoma: altering transforming growth factor-b signaling in hepatocarcinogenesis. Dig Dis 2011;29:284-8.
11. Meulmeester E, Ten Dijke P. The dynamic roles of TGF-β in cancer. J Pathol 2011;223:205-18.
12. Dong ZZ, Yao DF, Yao M, Qiu LW, Zong L, Wu W, et al. Clinical impact of plasma TGF-β1 and circulating TGF-βeta1 mRNA in diagnosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2008;7:288-95.
13. Chen Z, Xie B, Zhu Q, Xia Q, Jiang S, Cao R, et al. FGFR4 and TGF-β1 expression in hepatocellular carcinoma: correlation with clinicopatholog-ical features and prognosis. Int J Med Sci 2013;10:1868-75.
14. Bertran E, Crosas-Molist E, Sancho P, Caja L, Lopez-Luque J, Navarro E, et al. Overactivation of the TGF-β pathway confers a mesenchymal-like phenotype and CXCR4-dependent migratory properties to liver tumor cells. Hepatology 2013;58:2032-44.
15. Giannelli G, Bergamini C, Fransvea E, Sgarra C, Antonaci S. Laminin-5 with transforming growth factor-β1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology 2005;129:1375-83.
16. Sacco R, Leuci D, Tortorella C, Fiore G, Marinosci F, Schiraldi O, et al. Transforming growth factor β1 and soluble Fas serum levels in hepatocel-lular carcinoma. Cytokine 2000;12:811-4.
17. El-Tayeh SF, Hussein TD, El-Houseini ME, Amer MA, El-Sherbini M, Elshemey WM. Serological biomarkers of hepatocellular carcinoma in Egyptian patients. Dis Markers 2012;32:255-63.
18. Elgendy SM, Hessien M, Elsherbiny MM, Abd El-Salam IM, El-Attar IA, El-Asser Ael B. A panel of molecular markers in hepatitis C virus-related hepatocellular carcinoma. J Egypt Natl Canc Inst 2005;17:270-8.
19. Song BC, Chung YH, Kim JA, Choi WB, Suh DD, Pyo SI, et al. Transforming growth factor-β1 as a useful serologic marker of small hepatocellular carcinoma. Cancer 2002;94:175-80.
20. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-36.
21. Hsu CH, Shen YC, Lin ZZ, Chen PJ, Shao YY, Ding YH, et al. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepa-tocellular carcinoma. J Hepatol 2010;53:126-31.
22. Hsu C, Huang CL, Hsu HC, Lee PH, Wang SJ, Cheng AL. HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity. Cancer 2002;94:415-20.
23. Lin SD, Lin TH, Feng WC, Shao YY, Cheng AL, Hsu CH. Transforming growth factor-beta mediated epithelial to mesenchymal transition contributes to in vivo resistance to sorafenib in hepatocellular carcinoma. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar. 31-Apr. 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract No. 1904.
24. Shao YY, Huang CC, Lin SD, Hsu CH, Cheng AL. Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy. Clin Cancer Res 2012;18:3992-7.
25. Shao YY, Lu LC, Lin ZZ, Hsu C, Shen YC, Hsu CH, et al. Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems. Br J Cancer 2012;107:1672-7.
26. Massague J. TGF-β signalling in context. Nat Rev Mol Cell Biol 2012;13:616-30.
27. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009;69:7385-92.
28. Llovet JM, Pena CE, Lathia CD, Shan M, Meinhardt G, Bruix J, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepato-cellular carcinoma. Clin Cancer Res 2012;18:2290-300.
29. van Zijl F, Mall S, Machat G, Pirker C, Zeillinger R, Weinhaeusel A, et al. A human model of epithelial to mesenchymal transition to monitor drug efficacy in hepatocellular carcinoma progression. Mol Caner Ther 2011;10:850-60.
30. Fuchs BC, Fujii T, Dorfman JD, Goodwin JM, Zhu AX, Lanuti M, et al. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res 2008;68:2391-9.
31. Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, Lindsted T, et al. TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A 2010;107:15535-40.
32. Faivre SJ, Santoro A, Kelley RK, Merle P, Gane E, Douillard JV, et al. A phase 2 study of a novel transforming growth factor-b (TGF-β1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepa-tocellular carcinoma (HCC). J Clin Oncol 32, 2014(3 suppl): abstr LBA173.
33. Yasmin Anum MY, Looi ML, Nor Aini AH, Merican I, Wahidah A, Mohd Radzi AH, et al. Combined assessment of TGF-βeta-1 and alpha-fetopro-tein values improves specificity in the diagnosis of hepatocellular carcinoma and other chronic liver diseases in Malaysia. Med J Malaysia 2009;64:223-7.